Logo
Sponsored by:

Presented by:

Using Llama-VHH to optimize T-cell mediated immunotherapies

The potential of T-cell engaging VHH single-domain therapeutics


Your details:

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)

  Register

Overview

If you've already registered, please click here to log in to the webcast

The past 10 years have seen a rapid evolution of therapeutic T-Cell redirection immunotherapies culminating in the approval of two important new treatment modalities: Chimeric Antigen Receptor T-cells (CAR-T) and Bispecific T-cell Engagers (BiTE®s). Alternative scaffolds and antibody formats are being explored to further optimise tumour targeting of T-cell redirection therapies. Newer and more diverse formats for bispecific antibody T-cell engagers and CAR-T cells are being developed to enhance the therapeutic window, tune target affinity binding and enhance biomarker specificity to minimise off-target toxicity. The extension of bispecific antibody T-cell engagers and CAR-T to the treatment of solid tumours is a holy grail for immunotherapy as solid tumours present a significantly larger unmet medical need than haematological malignancies.

In this webcast, speakers will introduce the unique benefits of the VHH antibodies generated from the hLlamdA synthetic library and summarize how single domain VHH antibodies can be engineered to tune their binding selectivity and specificity for antigen targeting and be applied to optimize the next generation of these important new therapeutic modalities.

Discover:

  • What are VHHs?
  • What is the clinical and research landscape for CAR-T and T-cell engagers?
  • Means by which the shortfalls of current CAR-T and T-cell engaging therapies can be overcome through the incorporation of VHH
This webcast has been produced for Isogenica by Nature Research Custom Media. The sponsor retains sole responsibility for content. About this content.

Presenters

Presenter
Dr. Ed McGowan
Director, Antibody Discovery and Development
Isogenica
View Biography
Presenter
Dr. Mandeep Sehmi
Business Development Manager
Isogenica
View Biography
Presenter
Sarah Hiddleston
Science Journalist
Nature Research for Nature Middle East
View Biography